Overview
PYPD market data
Price History
PYPD price chart · 1M
- O
- 5.02
- H
- 5.11
- L
- 5.02
- C
- 5.11
- Vol
- 665.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $5.02
- Previous Close
- $5.15
- Day High
- $5.11
- Day Low
- $5.02
- 52 Week High
- $5.62
- 52 Week Low
- $3.68
- 7 Day Return
- +0.69%
- 30 Day Return
- +36.63%
- 90 Day Return
- +8.26%
- 1 Year Return
- +10.13%
- Daily Notional Volume
- $3.4K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.09 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.42 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.06 – $5.73 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $91.6M · P/B 6.29.
Company News
PolyPid Q2 EPS $(0.35) Beats $(0.38) EstimateBenzinga · Aug 12, 2026, 11:30 AM
PolyPid shares are trading higher after the company announced that the FDA accepted its New Drug Application and granted it a Priority Review for D-PLEX100Benzinga · Jul 29, 2026, 12:50 PM
PolyPid Announces FDA Acceptance Of Its New Drug Application With A Priority Review For D-PLEX100 For The Prevention Of Surgical Site Infections In Patients Undergoing Abdominal Colorectal Surgery; PDUFA Action Date Is November 28Benzinga · Jul 29, 2026, 12:34 PM
HC Wainwright & Co. Reiterates Buy on PolyPid, Maintains $13 Price TargetBenzinga · Jul 21, 2026, 3:58 PM
PolyPid shares are trading lower. The company announced it has entered into an exclusive commercial partnership agreement with Azurity Pharmaceuticals for the commercialization of D-PLEX100.Benzinga · Jul 21, 2026, 2:30 PM
PolyPid Signs Agreement With Azurity Pharmaceuticals To Commercialize D-PLEX100 In U.S., Canada To Prevent Surgical Site Infections; PolyPid To Receive $15M Upfront PaymentBenzinga · Jul 21, 2026, 11:32 AM
PolyPid Completes Its New Drug Application Submission On Rolling Review Basis Top FDA For D-PLEX100 To Prevent Surgical Site InfectionsBenzinga · Jun 1, 2026, 12:40 PM